LAVA Therapeutics (LVTX) announced that the Netherlands Enterprise Agency granted a full waiver of the final payment obligation related to the Innovation Credit, in the amount of $5.1 million. “As part of LAVA’s ongoing strategic review, we have implemented a targeted cost optimization initiative to enhance operational efficiency and financial flexibility,” said Steve Hurly, Chief Executive Officer of LAVA. “Securing the $5.1 million repayment waiver is a significant milestone in this effort. This waiver strengthens our balance sheet by eliminating this outstanding debt obligation. We are grateful for the opportunity to work with the RVO and be part of the Innovation Credit program.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LVTX:
- Hold Rating for LAVA Therapeutics Amid Strategic Review and LAVA-1266 Progress
- Lava Therapeutics Reports 2024 Financial Results
- Lava Therapeutics reports Q4 EPS (14c) vs. (24c) last year
- Lava Therapeutics sees cash runway into 2027
- Lava Therapeutics expects $1M of expenses related to restructuring plan